Issue 07

REGULATION AND LEGISLATION

Washington DC Democratic Party endorses psychedelic decriminalisation initiative.

Canada’s green party supports healthcare professionals who want access to psilocybin.

Michigan prosecutor announces he won’t pursue any psychedelic possession cases.

Psychedelic advocacy group releases handbook on enacting local decriminalisation.

Oregon Democratic Party endorses legal psilocybin therapy.

BUSINESS AND INVESTMENT

Field Trip Health commences trading on the CSE under ticker symbol FTRP.

Numinus commences mushroom cultivation at Health Canada approved lab.

Mind Cure receives Health Canada authorisation to sell its Moonbeam products.

MindMed partners with NYU to launch clinical psychedelic therapy training programmes.

AWAKN Life Sciences adds Professor Celia Morgan to its Scientific Advisory Board.

NeonMind signs psilocybin supply agreement with Psygen Labs for clinical trials.

Revive Therapeutics announces update on FDA phase 3 bucillamine COVID-19 trial.

MindMed and Lechti Lab announce R&D collaboration on psilocybin.

Psychedelic Science prepares clinical trials of psychedelic cacti-based products.

RESEARCH AND SCIENCE

Study suggests intravenous ketamine is effective at treating SRSE.

Studies on animal models find that ayahuasca is capable of forming brain cells and neurons.

New study finds subanesthetic ketamine effective in treating adult amblyopia.

New study examines if psilocybin can help treat cancer patients with depression.

Psychedelics in group therapy show promising results for HIV survivors.

Mushrooms spread spores across medicine, food, fashion and culture.

THE GLOBAL GATHERING OF INDUSTRY STAKEHOLDERS RETURNS THIS NOVEMBER

Taking place 17-20 as part of Prohibition Partners LIVE, The PSYCH Symposium will bring together distinguished industry thought leaders, rising entrepreneurs and experienced policymakers to share insights and help develop this emerging frontier.

Attendees will receive in-depth analysis on the everchanging regulatory landscape, a deep-dive into the most disruptive research and a first glance at the most exciting commercial opportunities in the market.

Super Early Bird tickets end tomorrow.

GET SUPER EARLY BIRD TICKETS NOW

THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION

The Psychedelics as Medicine Report: Second Edition provides a comprehensive overview of the clinical trials being carried out on psychedelic medicines and the impact that they could have if they were integrated into mainstream healthcare systems around the world.

The Psychedelics as Medicine Report: Second Edition also examines:

  • Proprietary consumer insights on attitudes, uses and behaviours
  • Deep dives into the most transformative compounds and companies
  • Key regulations, transformative trends and commercial opportunities

Download your free copy now.

THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION
Partner with us